Three bacteriophages (pink dots) were tested against a huge collection of Escherichia coli strains representing different serotypes. In combination the three bacteriophages kill most of the tested strains. The graph was generated using proprietary PhageSelector™ program developed by Intralytix, Inc.
Researchers from the University of Copenhagen have succeeded in targeting and killing a single bacterial species (E. coli) without causing harm to the surrounding community of commensal bacteria in a simulated small intestinal microbiome using a cocktail of viruses (bacteriophages). The study proved that this approach is as effective in killing the targeted E. coli as broad-spectrum antibiotics but has much gentler impact on the normal, and often beneficial, microflora compared to antibiotics.
The experiment underlines the potential of using bacteriophages for target-specific manipulation of complex microbial communities and potentially replacing or supplementing usage of antibiotics as therapeutic agent against bacterial diseases.
Imagine that you have become ill because you have eaten some food that contained pathogenic bacteria. You keep running to the toilet and you may also throw up. You go to the doctor and are prescribed broad-spectrum antibiotics, which – in addition to killing the bad bacteria in your intestinal flora – carpet bomb the complex community of commensal bacteria forming a healthy intestinal flora.
New research from the Department of Food Science (FOOD) at the University of Copenhagen suggests that, in the not-too-distant future, it might be possible to drink a cocktail of selective viruses (bacteriophages) that travel directly into the gut and kill the disease-causing bacteria, so you get better – without the use of antibiotics and without harming the beneficial commensal intestinal bacteria.
The researchers have come a step closer to this scenario.
“The research shows that we have an opportunity to kill specific bacteria without collateral damage to the other, and otherwise healthy, intestinal flora”, says Professor Dennis Sandris Nielsen from Department of Food Science at the University of Copenhagen.
He emphasizes that the result was created in a model of the small intestine; so the next step will be to test the study on mice and later on humans if such treatment is to be implemented.
Model of the small intestine
The model in which the research has been conducted, TSI, was developed at FOOD by postdoc Tomasz Cieplak, in connection with his PhD project, with Professor Dennis Sandris Nielsen as his supervisor.
3D representation of the TSI in vitro model. TSI consists of 5 elements: main unit, water bath, syringe pump station, nitrogen tank and computer which controls the whole setup. In the main unit, there are multiple reactors capable to test up to 5 samples at the same time. Illustration: Maja Czesnik
“The novelty of the TSI model is that it simulates the presence of the small intestinal microbiota, which has largely been overlooked in other models of the small intestine. Other models existing on the market simulate only the purely biophysical processes, such as bile salts and digestive enzymes or pH, but here we included this important aspect of human gut physiology to mimic the small intestine more closely”, says Cieplak.
The composition of the intestinal flora in the model is representative of how the intestinal flora could look in a healthy person. In the study, researchers have added E. coli bacteria to the intestinal flora, which they then attempted to kill by utilizing a targeted cocktail of viruses (bacteriophages) developed by the company Intralytix.
New research in an old method
Professor at the Department of Food Science at the University of Copenhagen Dennis Sandris Nielsen.
“Using bacteriophages to kill pathogenic bacteria is not new and has actually been used to treat food-borne illnesses and other diseases in Eastern Europe for almost a century, but it was not until relatively recently that this approach started to attract more widespread research interest”, says Dennis Sandris Nielsen
The research into combating infectious diseases with viruses was not as interesting because you already had an effective treatment with antibiotics.
“It is different today, where resistance to antibiotics is an increasing problem in modern medicine. At the same time, we have become more aware of how important the commensal bacteria in the gut are for our health”, says Nielsen.
Phages (bacteriophages) are viruses that attack bacteria – in this context, bacteria in our intestinal microbiome. The classic lytic phage attacks bacteria by attaching to the surface of the bacterium and injecting its genetic material into the bacterium. It takes over the bacterium’s metabolism and redirects it to create new viruses. The bacterial cell, now taken over by the phage, will explode and send a lot of new phages into the surrounding area, which can then attack new bacteria.
Postdoc at FOOD Tomasz Cieplak about the research and the TSI:
The Latest on: Bacteriophages
via Google News
The Latest on: Bacteriophages
- Angioplasty Gets a Boost from Smart Stents That Heal and Repair Damaged Tissueon April 8, 2021 at 5:00 am
These smart stents can heal blood vessels and repair damaged tissues ... Advanced stent technology comprises drug-releasing stents (drug eluting stents, DES) that prevent all cell growth. This is ...
- Smart Insulin Pens Market Emerging Technologies, Development Trends and Forecast to 2027on April 7, 2021 at 7:53 am
The global smart insulin pens market was valued at US$ 29.5 Mn in 2019 and is projected to reach US$ 73.8 Mn by 2027, expanding at a CAGR of 10.5% from 2020 to 2027. Smart insulin pens are devices ...
- Smart stent coatings release drugs for better artery healingon April 7, 2021 at 12:06 am
Scientists have developed a new type of smart stent that can help prevent some of the complications these implants bring. The stent is coated in a substance that minimizes the inflammatory response, ...
- NCSU scientists’ ‘smart-release’ trigger may provide benefits for heart, stentson April 6, 2021 at 10:20 am
Researchers from North Carolina State University have developed an exosome-coated stent with a "smart-release" trigger that could both prevent reopened blood vessels from narrowing and deliv ...
- Kindeva Drug Delivery and Cambridge Healthcare Innovations Limited to Collaborate on Development of Novel Dry-Powder Inhaler Producton April 6, 2021 at 6:07 am
which have the potential to incorporate SMART electronics and enable connectivity. Kindeva is a leading global contract development and manufacturing organization (CDMO) that has a legacy of solving ...
- Injectable Drug Delivery Market: Rising Incidence of Chronic Diseases to drive the marketon April 6, 2021 at 5:31 am
Rising prevalence of chronic diseases, technological advancements, growth of biologics, and demand for self-injecting drugs is likely to augment the ...
- Smart Syringe Market Size | Global Industry Analysis, Segments, Top Key Players, Drivers and Trends to 2027on April 6, 2021 at 2:17 am
Selbyville, Delaware, Market Study Report LLC recently added a new title on 2020-2027 Global Smart Syringe Market Report from its database. The report provides study with in-depth overview, describing ...
- Long Term Drug Rehab Inquiries Increasing According To TheRecover.comon April 5, 2021 at 12:04 pm
National addiction and mental health news provider, The Recover, indicated that they have experienced an increase in their call volume from individuals looking specifically for long term drug rehabs.
- PatchRx Ensures Individuals Take Their Medication On Time With Smart Technologyon April 2, 2021 at 6:07 am
Non-adherence to taking prescription medication costs our U.S. healthcare system billions of dollars and results in hundreds of thousands of preventable deaths. Two San Antonio entrepreneurs have ...
via Bing News